Ontology highlight
ABSTRACT:
PROVIDER: PRJNA362958 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR5196130_1.fastq.gz | Fastqsanger.gz | |||
| SRR5196130_2.fastq.gz | Fastqsanger.gz | |||
| SRR5196140_1.fastq.gz | Fastqsanger.gz | |||
| SRR5196140_2.fastq.gz | Fastqsanger.gz | |||
| SRR5196150.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 58 |
Similar Datasets
Project description:We carried out Massive Parallel Sequencing (MPS) to reveal circulating miRNA profiles of 96 patients to distinguish the radiographic and non-radiographic axial spondyloarthritis. The sequencing platform identified 1900 miRNA species, out of which 432 miRNAs were present with the base mean, computed by DESeq2, more than 10. We identified 48 miRNAs, which were different in PBMCs in patients with axial spondyloarthritis compared to healthy controls.
2024-01-09 | GSE252708 | GEO
Project description:Sickle cell disease (SCD) is a red blood cell disorder associated with hemolysis and inflammation affecting hematopoietic system homeostasis. While both innate and T cell driven adaptive immune responses are involved in driving SCD-linked inflammation, the involvement of the B cell compartment in the pathophysiology of SCD, especially in pediatric patients, is much less understood. To determine the range of immune changes, we assessed the frequency of twelve immune populations via flow cytometry and levels of B cell related cytokines of the peripheral blood (PB) of pediatric (n=13) and adult (n=12) patients with SCD on hydroxyurea as compared to pediatric (n=5) and adult (n=10) race-matched controls. We also evaluated bulk RNA sequencing of the PB of pediatric SCD patients and controls. The majority of SCD patients carried the hemoglobin SS genotype (92.3% pediatrics and 66.7% adults). Mean Hydroxyurea dose was 23.4 mg/kg and 20.0 mg/kg for pediatric SCD (PSCD) and adult SCD (ASCD), respectively. Laboratory data revealed anemia with mean hemoglobin 9.4 g/dl in PSCD and 9.7 g/dl in ASCD with elevated hemolysis in pediatric and adult SCD with mean reticulocyte count of 7.1% in PSCD and 8.8% in ASCD with mean absolute reticulocyte count (ARC) 203 ± 94 for pediatric SCD and 214 ± 169 for adult SCD. Flow cytometry data revealed 1.9-fold increase (p value 0.012) of CD3+CD4+ cells in pediatric SCD versus pediatric controls; this change was not seen in adult SCD versus adult controls (decrease 17%, p value 0.302). Pediatric SCD patients had 3.5-fold increase (p=0.005) in CD19+ B cells without further increase in differentiated B cells, and this change was not seen in adult SCD versus adult controls (increase 7%, p value 0.815). We performed bulk RNA sequencing on the PB of pediatric patients with SCD as compared to the pediatric controls. Obtained transcriptomic data indicated significant changes in transcripts linked to humoral immunity. Over Representation Analysis (ORA) of cell type revealed upregulation of transcripts linked to pro-B cells (27 genes, top 3:E2F2,RAD51,ASPM) and plasma cells (37 genes, top 3:IGF1,TNFRSF17,DERL3). Analysis of B cell related cytokines revealed significant increase in IL2 (p value 0.013), IL4 (p value 0.026), TNFβ (p value 0.039), and IL13 (p value 0.034) inpediatric SCD versus pediatric controls withno significance for these cytokines in adult SCD versus adult controls. BAFF was elevated in both pediatric and adult SCD versus age-matched controls (p value0.041 and p value 0.005, respectively). In sum, our data indicate significant changes in CD4+ and CD19+ cells andsuggest significant alteration of the B cell maturation in pediatric SCD samples. Our findings point to previously unreported effect of SCD on the humoral immune system in children with SCD treated with hydroxyurea, warranting further investigation.
2025-05-15 | GSE262659 | GEO
Project description:Association of juvenile spondyloarthritis (jSpA) with the HLA-B27 genotype is well established, but there is little knowledge of other genetic factors with a role in disease development. The aim of the present study was to identify and confirm gene signatures and novel biomarkers in various cohorts of untreated and treated patients diagnosed with jSpA and other forms of juvenile idiopathic arthritis (JIA). DNA microarray gene expression was performed in 11 patients with jSpA and in four healthy controls, along with bioinformatics analysis of retrieved data (DAVID, GSEA, IPA).
2014-10-31 | GSE58667 | GEO
Project description:RNA-sequencing of pediatric idiopathic dilated cardiomyopathy patients and healthy controls
| PRJNA388098 | ENA
Project description:In this study we performed the first global RNA-seq analysis in pediatric to young-adult patients with sclerotic-type graft-versus-host disease/scGvHD (n=7), age- and sex-matched to 8 healthy controls and 10 patients with atopic dermatitis/AD. Differentially expressed genes (DEGs) were defined based on fold changes/FCH>1.5 and false discovery rate/FDR<0.05 criteria. We found robust and significant Th1 (e.g. CXCR9/10/11, IFNG) and OX40-skewing in ScGvHD (e.g. OX40L, TLSP, IL-33) that sometimes exceeded that in AD and was validated on RT-PCR.
2023-10-11 | GSE230200 | GEO
Project description:Genome wide DNA methylation profiling of FASD patients versus healthy unexposed controls. The Illumina Infinium 450k Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 485,000 CpGs in peripheral blood samples. Samples included 28 healthy controls and7 FASD patients.
2019-03-18 | GSE113012 | GEO
Project description:Deficiency in the X-linked inhibitor of apoptosis protein (XIAP) is the cause for the X-linked lymphoproliferative syndrome 2 (XLP2). About one third of all patients suffers from severe and therapy refractory inflammatory bowel disease (IBD), but the exact pathogenesis remains undefined. We examined the differences in gene expression of pediatric XLP2 patients with IBD to healthy controls and pediatric IBD patients.
2021-09-20 | GSE183069 | GEO
Project description:Expression data from mesenchymal stromal cells derived from pediatric leukemia patients and healthy pediatric controls
| PRJNA394243 | ENA